Reaction
Exposure Via Body Fluid reporting signals
As of the last recalculation, Exposure Via Body Fluid appears in 782 FAERS reports alongside 13 co-occurring drug terms. The strongest observed disproportionality signal is ENTECAVIR (PRR 103.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Entecavir | 43 | 103.7 | 104.0 |
| Dasatinib | 64 | 49.8 | 49.9 |
| Thalidomide | 42 | 32.1 | 32.2 |
| Buprenorphine Hydrochloride, Naloxone Hydrochloride | 26 | 29.6 | 29.7 |
| Eculizumab | 48 | 25.0 | 25.0 |
| Isotretinoin | 38 | 21.4 | 21.5 |
| Ravulizumab | 10 | 19.9 | 20.0 |
| Sodium Oxybate | 43 | 18.3 | 18.3 |
| Sofosbuvir | 13 | 17.8 | 17.8 |
| Velpatasvir And Sofosbuvir | 8 | 16.8 | 16.8 |
| Ipilimumab | 25 | 15.9 | 15.9 |
| Asfotase Alfa | 4 | 10.7 | 10.7 |
| Nivolumab | 34 | 9.7 | 9.7 |